Novel drug delivery systems (NDDS) constitute the main stay of pharmaceutical research and development. Various novel drug delivery systems are existing in the pharmaceuticals but they fail to overcome the problems like life cycle management, patient compliance, bioavailability, stability, difficulty in combination drug therapies and reduction in generic competition. Innercap technology which is also known as multi-phase and multi-compartment dosage form offers an opportunity to overcome those problems and increase their pipeline of products, utilize more promising compounds and increase the difficulty in counterfeiting high value products. This multi-phased, multi-compartmentalized capsular based drug delivery system will license to enhance pharmaceutical and biopharmaceutical products. It is a very effective way to deliver multiple active chemical compounds in different physical phases with controlled release profiles. This novel delivery system provides the pharmaceutical and biopharmaceutical industries with beneficial solutions to the industry’s highly publicized requirement to repackage and reformulate existing patented blockbuster drugs with expiring patents over the next five years. Innercap technology seeks combination drug products that provide meaningful patient, healthcare provider and physician benefits, and will be responsive to effective marketing campaigns. Innercap technology provides solutions to patients, healthcare providers, physicians, research and development through the development of combination drug therapies. It also offers partners the benefit of a strong intellectual property position, in relation to the Innercap delivery system and a range of delivery targets. With an aging population and healthcare costs on the rise, the healthcare industry will look for pharmaceutical products that increase compliance and decrease healthcare costs.
Loading....